TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31550810
Drug: Tailored quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored quadruple therapy based on clarithromycin sensitivity
Study: 31550810
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving clarithromycin quadruple therapy (PPI, amoxicillin, clarithromycin, bismuth)
Study: 28755406
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg apple polyphenols for 8 weeks
Study: 23557482
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention consisting of up to six face-to-face counseling sessions with a trained practice nurse, followed by three-monthly sessions by phone.
Study: 21538030
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg daily for 8 weeks
Study: 17328057
Drug: Onercept 100
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onercept 100 mg
Study: 15316583
Drug: Lactobacillus casei
Normalized name: Lactobacillus Casei
DrugBank: Lactobacillus casei (DB16541)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus casei fermented milk (108 ‐ 1010/g), 3 cups per day for 8 weeks
Study: 7612535
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g four times daily on days 1 to 4 for two cycles)
Study: 7612535
Drug: Norethisterone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone (5 mg twice a day on days 19 and 26 for two cycles)
Study: 2653386
Drug: L-DOPA and
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA and 5 HTP in small doses
Study: 29549588
Drug: Adapalene 0.3%/Benzoyl
Normalized name: ADAPALENE 0.3%/BENZOYL PEROXIDE 2.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel (A0.3/BPO2.5)
Study: 27028749
Drug: Umeclidinium/Vilanterol (UMEC/VI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg
Study: 27028749
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Study: 27028749
Drug: Tiotropinium (TIO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropinium (TIO) 18 mcg + Indacaterol (IND) 150 mcg
Study: 24674732
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Evicel (fibrin sealant)
Study: 22331237
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (concomitant NP and Rh-endostatin)
Study: 22331237
Drug: Rh-endostatin combined
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rh-endostatin combined with chemotherapy
Study: 16381266
Drug: Bupivacaine (0.15%;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml) + Epinephrine (1.7 microg/ml; 1:600,000)
Study: 16381266
Drug: Bupivacaine (0.15%;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (0.15%; 15 mg) + Fentanyl (0.0002%; 2 microg/ml)
Study: 8561257
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) 300 mg weekly
Study: 2539655
Drug: Etoposide 300
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide 300 mg/m2 for two days
Study: 2539655
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine 1 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 1000 mg/m2 (VAC)
Study: 2539655
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (VAC)
Study: 71973
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg flurbiprofen daily for 2 weeks
Study: 30745014
Drug: Furosemide (in-hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (in-hospital dose)
Study: 31290727
Drug: PD-L1 monoclonal
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PD-L1 monoclonal antibody-conjugated miR-130a/oxaliplatin-loaded immunoliposomes (PD-miOXNP)
Study: 23011843
Drug: Bupivacaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (300 mL of 0.5% bupivacaine)
Study: 23011843
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (300 mL of 0.9% normal saline solution)
Study: 18081859
Drug: Enamel matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enamel matrix protein derivative (EMD) + low-level laser therapy (LLLT)
Study: 3110307
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum gamma globulin (ISG) 5 or 10 ml
Study: 3110307
Drug: Immune serum
Normalized name: IMMUNE SERUMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune serum gamma globulin (ISG) 2 ml
Study: 15924594
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily (continuous)
Study: 15924594
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice-daily (continuous)
Study: 15924594
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (during the 4-week symptom control phase)
Study: 10650568
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g/tid p.o. before meals)
Study: 1967882
Drug: 1% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% hydrogen peroxide in a stabilized lipid cream applied for 2 min before UVA exposure
Study: 6160324
Drug: Intravenous pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pindolol (0.4 mg)
Study: 6160324
Drug: Oral pindolol
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pindolol (5 mg, t.i.d.)
Study: 30680547
Drug: Vitamin B12-fortified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12-fortified toothpaste (100 µg cyanocobalamin/g)
Study: 23318812
Drug: Bupivacaine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (30 ml bolus at 2.5 mg/ml followed by continuous infusion at 5 ml/h for 48 hours)
Study: 23318812
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline, same administration as bupivacaine)
Study: 21111685
Drug: Prednisolone 20
Normalized name: prednisolone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks (n = 39)
Study: 19505986
Drug: Long-acting β-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting β-agonist (LABA) with mandatory inhaled corticosteroid (ICS) therapy
Study: 16760520
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg three times a day
Study: 16760520
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg two times a day
Study: 9163658
Drug: Sparfloxacin (SPX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (SPX), 400 mg
Study: 9163658
Drug: Ciprofloxacin (CPX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (CPX), 500 mg
Study: 8142159
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (96 mg IV bolus, followed by 96 mg orally for 3 days, then tapered over 10 days)
Study: 8142159
Drug: No dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: No dexamethasone therapy (control group)
Study: 3061316
Drug: IgE and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE and IgG4 antibodies
Study: 26237806
Drug: Herbal- and
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal- and peloidotherapy as a combination treatment
Study: 26237806
Drug: Upgraded combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upgraded combination scheme for the treatment of chronic cystitis
Study: 23011683
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body vibration (WBV) therapy, 20 min/day, 5 days/week for 12 months
Study: 18602725
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of 10 million IU of IFNalpha
Study: 16809727
Drug: Trastuzumab added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab added concurrently, sequentially, or not at all as adjuvant therapy
Study: 15323468
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgical intervention and radiotherapy
Study: 8646692
Drug: Treatment variables
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment variables (not specified)
Study: 6088368
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine three times a day and 400 mg at night
Study: 30039902
Drug: EPG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPG therapy
Study: 30039902
Drug: EPG-informed conventional
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPG-informed conventional therapy
Study: 30332430
Drug: 150 min/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 min/week of aerobic exercise (low-dose) for six months
Study: 30332430
Drug: 300 min/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 min/week of aerobic exercise (high-dose) for six months
Study: 27258504
Drug: Ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor loading dose of 360 mg
Study: 27258504
Drug: Ticagrelor loading
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor loading dose of 180 mg (conventional)
Study: 21872485
Drug: Triterpene ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triterpene ointment (OG-S10) applied at 100 mg/cm² for 14 days
Study: 21872485
Drug: Triterpene ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triterpene ointment (OG-S10)
Study: 19932542
Drug: Adalimumab, 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab, 24 mg/m², every 14 days for 16 weeks (total, 9 doses)
Study: 15909266
Drug: Artesunate-clindamycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-clindamycin (2 mg/kg artesunate and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Study: 15909266
Drug: Quinine-clindamycin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine-clindamycin (15 mg/kg quinine and 7 mg/kg clindamycin per dose, twice daily for 3 days)
Study: 9578170
Drug: Ceftazidime 320
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 320 mg/kg/day
Study: 9578170
Drug: Ceftazidime 150
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 150 mg/kg/day
Study: 28338849
Drug: lifestyle Matters
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lifestyle Matters intervention (weekly group sessions over 4 months and one to one sessions)
Study: 20854334
Drug: CBT4CBT (computerized
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT (computerized cognitive behavioral therapy)
Study: 25930952
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (methadone maintenance treatment alone)
Study: 19910808
Drug: 15 degrees
Normalized name: ALUMINUM SESQUICHLOROHYDRATE 15.2 g in 100 g TOPICAL AEROSOL, SPRAY [Degree]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 degrees C standard refrigerant gel pack (P)
Study: 1539751
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg/week
Study: 1539751
Drug: Chloroquine 300
Normalized name: chloroquine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 300 mg/week
Study: 1539751
Drug: Chloroquine 600
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine 600 mg (post-treatment)
Study: 15967846
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg PO BID
Study: 15967846
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg PO TID
Study: 15967846
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg PO BID plus Captopril 50 mg PO TID
Study: 11900261
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - 6-month supervised outpatient exercise program (3 weekly sessions of aerobic and strengthening training on non-dialysis days)
Study: 7428365
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 1 (9-12 weeks pregnant)
Study: 7428365
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg vaginal suppository of 15-methyl prostaglandin F2 alpha-methyl ester for Group 2 (13-14 weeks pregnant)
Study: 7428365
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (1 mg and 1.5 mg)
Study: 30453788
Drug: 12-h acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-h acetylcysteine regimen (200 mg/kg over 4 h, 50 mg/kg over 8 h)
Study: 30453788
Drug: 20-h acetylcysteine
Normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20-h acetylcysteine regimen (200 mg/kg over 4 h, 100 mg/kg over 16 h)
Study: 26887209
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (comprehensive treatment only)
Study: 23063327
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg/day for the first week, and 20 mg/day for the rest of the trial)
Study: 21515866
Drug: Conivaptan hydrochloride
Normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conivaptan hydrochloride 20 mg once daily
Study: 21515866
Drug: Conivaptan hydrochloride
Normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conivaptan hydrochloride 20 mg twice daily
Study: 29423372
Drug: Strengthened inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthened inhalation therapy for asthma
Study: 26774179
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter; n = 69)
Study: 26774179
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/d for the first 15 days, 40 mg/d thereafter)
Study: 18319306
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d for 2 yr, then 850 mg/d for 2 yr)
Study: 12886210
Drug: No thermocycling
Approvals — FDA: no, EMA: no, PMDA: no
Description: No thermocycling treatment
Study: 10073863
Drug: High-density lipoprotein
Normalized name: Cholesterol in High-density lipoprotein (HDL) 2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-density lipoprotein (HDL) raising treatment with nicotinic acid
Study: 10073863
Drug: Low-density lipoprotein
Normalized name: Low-density lipoprotein receptor kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-density lipoprotein (LDL) lowering therapy with hydroxymethylglutaryl-coenzyme A reductase inhibitor
Study: 10073863
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy (beta-carotene and vitamins E and C)
Study: 10073863
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (warfarin)
Study: 27031850
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with chemotherapy
Study: 22078631
Drug: Physiological modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological modulators (PMs) with antioxidant action (MF Templar®)
Study: 17890871
Drug: Continuous frusemide
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous frusemide infusion
Study: 17890871
Drug: Regular intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intermittent intravenous boluses of frusemide
Study: 9696954
Drug: Controlled-release levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal (30 min before ingestion)
Study: 9696954
Drug: Controlled-release levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after fasting (2 hours after ingestion)
Study: 9696954
Drug: Controlled-release levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after a standard meal
Study: 9696954
Drug: Controlled-release levodopa/carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release levodopa/carbidopa 200/50 mg after fasting
Study: 29629694
Drug: Gastric lavage
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric lavage with normal saline at 10 mL per kg body weight (n=350)
Study: 23448313
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine prescription from clinician A
Study: 23448313
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine prescription from clinician B
Study: 23448313
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicine prescription from clinician C
Study: 16968585
Drug: NXY-059 (8-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: NXY-059 (8-h and 72-h intravenous infusions)
Study: 16968585
Drug: Placebo (8-h
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8-h and 72-h intravenous infusions)
Study: 2722729
Drug: Cefmetazole (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (3 doses of 1 g)
Study: 2722729
Drug: Cefoxitin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (3 doses of 2 g)
Study: 23517585
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy for at least two months
Study: 23517585
Drug: Peak vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak vascular response following breath hold tests in OSA patients before CPAP therapy
Study: 15031595
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial infusion chemotherapy (TAI)
Study: 11223117
Drug: Bromperidol (6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol (6, 12, or 18 mg/day for 3 weeks)
Study: 11223117
Drug: Nemonapride (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonapride (18 mg/day for 3 weeks)
Study: 8425670
Drug: Ponalrestat 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponalrestat 600 mg once daily
Study: 31982096
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of Parent Management Training (PMT) and child Cognitive Behavioral Therapy (CBT)
Study: 31982096
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of PMT and child CBT
Study: 29265084
Drug: Noophen with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noophen with standard therapy (n=33)
Study: 29265084
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy only (Control group, n=20)
Study: 21306285
Drug: Proactive multifactorial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive multifactorial risk factor intervention strategy using single‐pill amlodipine/atorvastatin (5/10, 10/10 mg)
Study: 18769080
Drug: Midazolam 50
Normalized name: midazolam 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 50 microg/kg with normal saline 1 ml/kg
Study: 18769080
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% 1 ml/kg
Study: 14614669
Drug: Intranasal mupirocin
Normalized name: Mupirocin
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal mupirocin ointment, twice daily for 2 weeks
Study: 10781652
Drug: Hormonal replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal replacement therapy with oral 17beta-estradiol or transdermal 17beta-estradiol, and oral norethisterone.
Study: 26449959
Drug: Methylergonovine and
Normalized name: methylergonovine
DrugBank: Methylergometrine (DB00353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylergonovine and oxytocin infusion
Study: 26449959
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion only